<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55011810"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<reference>Proc. Nat. Acad. Sci. USA<lb/> Vol. 71, No. 12, pp. 5078-5082, December 1974<lb/></reference>

	<docTitle>
	<titlePart>A New Antitumoral Agent: 9-Hydroxyellipticine. Possibility of a Rational<lb/> Design of Anticancerous Drugs in the Series of DNA Intercalating Drugs<lb/> [cancer chemotherapy/ethidium bromide/DNA unwinding/pyrido (4-3b) carbazole]<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>JEAN-BERNARD LE PECQ*, NGUYEN-DAT-XUONGt, CHARLES GOSSE*, AND CLAUDE PAOLETTI*<lb/></docAuthor>
	</byline>

	<byline>
	<affiliation>* Laboratorie de Pharmacologie Molbculaire n1147 du CNRS, Institut Gustave-Roussy,</affiliation>
	</byline>

	<address>Villejuif 94800, France;</address>

	<byline>
	<affiliation>and t Institute de<lb/> Chimie des Substances Naturelles du CNRS,</affiliation>
	</byline>

	<address>Gif-Sur-Yvette 91190, France<lb/></address>

	<note type="submission">Communicated by F. Jacob, September 16, 1974<lb/></note>

	<div type="abstract">ABSTRACT The designing of DNA intercalating drugs<lb/> with high DNA affinity in the series of ellipticine has led<lb/> to a new antitumoral agent, 9-hydroxyellipticine, which<lb/> has a high DNA affinity, a high activity on L 1210 mice<lb/> leukemia, and a lack of toxicity at therapeutic dose. The<lb/> possible correlations among chemical structure, DNA re-<lb/>activity, and pharmacological activity of DNA inter-<lb/>calating drugs are discussed.<lb/></div>

		</front>
	</text>
</tei>
